Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

CompletedOBSERVATIONAL
Enrollment

1,481

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

March 18, 2020

Study Completion Date

August 26, 2020

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by the treating physician

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY